

10 July 2020

ASX ANNOUNCEMENT

AVR host TAVR KOL Symposium moderated by Credit Suisse – ASX Heading Correction

Anteris Technologies Ltd (ASX: AVR) advises that the following regarding the attached Announcement released on 9 July 2020 – the headline on the announcement should be as below:

AVR host TAVR KOL Symposium moderated by Credit Suisse

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.

Authorisation and additional information

This announcement was authorised by Mr Stephen Denaro, Company Secretary.

For more information:

Ms Kyahn Williamson

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 401 018 828

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech

Anteris Technologies Ltd


Registered Office:

Suite 302, Level 3 Toowong Tower, 9 Sherwood Road, Toowong QLD 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@anteristech.com W: anteristech.com





9 July 2020

ASX ANNOUNCEMENT

Anteris Technologies to Host TAVR Key Opinion Leader Symposium Moderated by Matt Miksic of Credit Suisse on 20 July 2020

Next Generation Technologies for the era of TAVR in Younger Low-Risk Patients with Aortic Stenosis

Anteris Technologies Ltd (ASX:AVR), a structural heart company advancing the DurAVR™ valve, a novel aortic valve replacement solution, announced today that it will host a key opinion leader symposium on Monday 20 July 2020 at 11:00 a.m. USA EDT (Tuesday 21 July at 1:00 a.m. AEST).

To register for the event, please visit the following website:

<https://bit.ly/38CGeDA>

A recording will be made available after the event.

The symposium, entitled “**Next Generation Technologies for the era of TAVR in Younger Low-Risk Patients with Aortic Stenosis,**” is intended to provide investors and analysts with a comprehensive profile of current trends in the use of Transcatheter Aortic Valve Replacement (TAVR), and the future of this technology to treat younger, low-risk patients with aortic stenosis. A key area of emphasis will be addressing how current TAVR solutions are suitable for this newly approved patient demographic, what challenges they have, and what are the leading next generation technologies that are in development. The forum will be moderated by Matt Miksic, Senior Analyst at Credit Suisse, and will feature the following key opinion leaders:

Dr Samir Kapadia, MD (Cleveland Clinic, Cleveland, OH)
Dr Michael Reardon, MD (Houston Methodist, Houston, TX)
Dr Paul Sorajja, MD (Minneapolis Heart Institute Foundation, Minneapolis, MN)

In addition, Anteris will provide an update on its TAVR research & development program, as well as an update on its ongoing first-in-human trial of its ADAPT® 3D single-piece aortic valve for Surgical Aortic Valve Replacement (SAVR) procedures.

Anteris Technologies Ltd


Registered Office:

Suite 302, Level 3 Toowong Tower, 9 Sherwood Road, Toowong QLD 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@anteristech.com W: anteristech.com





About Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd is a structural heart company focused on delivering clinically superior solutions that create life-changing outcomes for patients. Its ADAPT® tissue platform, a next generation technology with zero DNA and zero glutaraldehyde, is the only bioscaffold to demonstrate zero calcification after 10 years of use in complex cardiac surgery. With these advantages, Anteris's best-in-class ADAPT® tissue combined with its valve design has the potential to solve the problems associated with current aortic valve replacement options which are durability and preventing valve degradation.

Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 401 018 828

www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech

For webinar specific items:

Jason Wong
Blueprint Life Science Group
E: jwong@bplifescience.com
P: +1 415 375 3340 Ext. 4

